After long review, we have decided to make the change from using a 503A compounding pharmacy to a 503B pharmacy and the integration of new advancements in weight loss medications.
In a groundbreaking three-year clinical trial, tirzepatide, a dual-action medication originally developed to treat type 2 diabetes, has shown remarkable efficacy in preventing the onset of the disease. This study,
Continue readingTirzepatide Demonstrates Diabetes Prevention in Landmark Three-Year Study
A clinical trial investigating the experimental weight loss drug retatrutide suggests it may not only prevent the progression of liver disease but potentially reverse it. According to Dr. Arun Sanyal,
Continue readingExperimental Weight Loss Drug Shows Promise in Treating Liver Disease
The U.S. Food and Drug Administration (FDA) has approved Zepbound (Tirzepatide), a weight loss medication as the first prescription treatment specifically for obstructive sleep apnea (OSA) in adults with obesity.
Continue readingFDA Approves Tirzepatide for Treating Obstructive Sleep Apnea in Adults with Obesity